MNMD
Price
$9.13
Change
+$0.25 (+2.82%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
675.66M
71 days until earnings call
ZLDPF
Price
$68.81
Change
+$2.81 (+4.26%)
Updated
Aug 28 closing price
Capitalization
4.85B
Interact to see
Advertisement

MNMD vs ZLDPF

Header iconMNMD vs ZLDPF Comparison
Open Charts MNMD vs ZLDPFBanner chart's image
Mind Medicine (MindMed)
Price$9.13
Change+$0.25 (+2.82%)
Volume$4.66K
Capitalization675.66M
Zealand Pharma A/S
Price$68.81
Change+$2.81 (+4.26%)
Volume$153
Capitalization4.85B
MNMD vs ZLDPF Comparison Chart in %
Loading...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNMD vs. ZLDPF commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNMD is a StrongBuy and ZLDPF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (MNMD: $8.88 vs. ZLDPF: $68.81)
Brand notoriety: MNMD and ZLDPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNMD: 169% vs. ZLDPF: 28%
Market capitalization -- MNMD: $675.66M vs. ZLDPF: $4.85B
MNMD [@Biotechnology] is valued at $675.66M. ZLDPF’s [@Biotechnology] market capitalization is $4.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNMD’s FA Score shows that 0 FA rating(s) are green whileZLDPF’s FA Score has 2 green FA rating(s).

  • MNMD’s FA Score: 0 green, 5 red.
  • ZLDPF’s FA Score: 2 green, 3 red.
According to our system of comparison, ZLDPF is a better buy in the long-term than MNMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNMD’s TA Score shows that 4 TA indicator(s) are bullish while ZLDPF’s TA Score has 5 bullish TA indicator(s).

  • MNMD’s TA Score: 4 bullish, 4 bearish.
  • ZLDPF’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ZLDPF is a better buy in the short-term than MNMD.

Price Growth

MNMD (@Biotechnology) experienced а -12.86% price change this week, while ZLDPF (@Biotechnology) price change was +12.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

MNMD is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLDPF($4.85B) has a higher market cap than MNMD($676M). MNMD YTD gains are higher at: 27.586 vs. ZLDPF (-32.776). ZLDPF has higher annual earnings (EBITDA): 7.27B vs. MNMD (-110.19M). ZLDPF has more cash in the bank: 16.6B vs. MNMD (183M). MNMD has less debt than ZLDPF: MNMD (41.2M) vs ZLDPF (397M). ZLDPF has higher revenues than MNMD: ZLDPF (9.11B) vs MNMD (0).
MNMDZLDPFMNMD / ZLDPF
Capitalization676M4.85B14%
EBITDA-110.19M7.27B-2%
Gain YTD27.586-32.776-84%
P/E RatioN/A4.75-
Revenue09.11B-
Total Cash183M16.6B1%
Total Debt41.2M397M10%
FUNDAMENTALS RATINGS
MNMD vs ZLDPF: Fundamental Ratings
MNMD
ZLDPF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
34
Fair valued
PROFIT vs RISK RATING
1..100
9372
SMR RATING
1..100
9819
PRICE GROWTH RATING
1..100
4459
P/E GROWTH RATING
1..100
10025
SEASONALITY SCORE
1..100
3890

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZLDPF's Valuation (34) in the null industry is in the same range as MNMD (35). This means that ZLDPF’s stock grew similarly to MNMD’s over the last 12 months.

ZLDPF's Profit vs Risk Rating (72) in the null industry is in the same range as MNMD (93). This means that ZLDPF’s stock grew similarly to MNMD’s over the last 12 months.

ZLDPF's SMR Rating (19) in the null industry is significantly better than the same rating for MNMD (98). This means that ZLDPF’s stock grew significantly faster than MNMD’s over the last 12 months.

MNMD's Price Growth Rating (44) in the null industry is in the same range as ZLDPF (59). This means that MNMD’s stock grew similarly to ZLDPF’s over the last 12 months.

ZLDPF's P/E Growth Rating (25) in the null industry is significantly better than the same rating for MNMD (100). This means that ZLDPF’s stock grew significantly faster than MNMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNMDZLDPF
RSI
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 5 days ago
55%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
90%
Bearish Trend 5 days ago
69%
Momentum
ODDS (%)
Bearish Trend 5 days ago
81%
Bullish Trend 5 days ago
57%
MACD
ODDS (%)
Bearish Trend 5 days ago
84%
Bullish Trend 5 days ago
62%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
86%
Bullish Trend 5 days ago
57%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
87%
Bullish Trend 5 days ago
58%
Advances
ODDS (%)
Bullish Trend 12 days ago
84%
Bullish Trend 16 days ago
72%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
N/A
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
90%
Bearish Trend 5 days ago
63%
Aroon
ODDS (%)
Bullish Trend 5 days ago
83%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IGNIX18.740.09
+0.48%
Macquarie Natural Resources I
DGOYX45.92N/A
N/A
Davis Opportunity Y
HFQAX7.02-0.02
-0.28%
Janus Henderson Global Equity Income A
FAPKX13.00-0.06
-0.46%
Fidelity Advisor Healthy Future C
CIPSX21.99-0.14
-0.63%
Champlain Small Company Adv

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with OCUL. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
-9.20%
OCUL - MNMD
53%
Loosely correlated
-2.48%
RXRX - MNMD
51%
Loosely correlated
-3.39%
ATAI - MNMD
51%
Loosely correlated
-1.51%
EYPT - MNMD
50%
Loosely correlated
-0.26%
RCUS - MNMD
50%
Loosely correlated
-0.19%
More

ZLDPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLDPF has been loosely correlated with IMRN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLDPF jumps, then IMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLDPF
1D Price
Change %
ZLDPF100%
N/A
IMRN - ZLDPF
52%
Loosely correlated
+0.55%
MNMD - ZLDPF
32%
Poorly correlated
-9.20%
VICP - ZLDPF
28%
Poorly correlated
N/A
GLSI - ZLDPF
26%
Poorly correlated
+0.17%
LTRN - ZLDPF
23%
Poorly correlated
+0.49%
More